---
layout: default
title: Misoprostol
parent: 僅模型預測 (L5)
nav_order: 94
evidence_level: L5
indication_count: 2
---

# Misoprostol
{: .fs-9 }

證據等級: **L5** | 預測適應症: **2** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Misoprostol: Drug Repurposing Evaluation — Insufficient Data to Generate Prediction Report

## One-Sentence Summary

Misoprostol (DrugBank ID: DB00929) is a prostaglandin E1 analogue with established clinical use in gastroduodenal protection and obstetric indications, but is currently **not approved in Taiwan**.
The TxGNN model returned **no predicted new indications** for this drug in the current pipeline run, and key data items including mechanism of action and safety labelling are missing — making a full repurposing evaluation impossible at this stage.
No clinical trial or literature evidence tables can be generated until predicted indications are available.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No approved indication on record (Taiwan: not marketed) |
| Predicted New Indication | None returned by TxGNN |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction unavailable; no supporting studies |
| Taiwan Market Status | ✗ Not marketed (0 authorizations) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The TxGNN pipeline returned an empty `predicted_indications` list for Misoprostol. This can occur for several reasons:

1. **Knowledge graph coverage gap**: Misoprostol may not be sufficiently represented in the underlying biomedical knowledge graph used by TxGNN (e.g., missing drug–gene–disease edges), causing the model to output no high-confidence candidates.
2. **Missing MOA data**: Mechanism of action data was not retrieved from DrugBank during this pipeline run. MOA edges are critical features for TxGNN inference; their absence can suppress or distort predictions.
3. **No Taiwan regulatory anchor**: Because Misoprostol has no TFDA-approved licence, no indication node could be used as a starting point for similarity-based repurposing.

Currently, detailed mechanism of action data is not available. Based on known pharmacological class, Misoprostol is a synthetic prostaglandin E1 analogue; its established clinical roles include NSAID-induced gastric ulcer prevention, cervical ripening, labour induction, and management of postpartum haemorrhage. Mechanistically it acts on EP receptors, modulating smooth muscle tone and mucosal cytoprotection — both of which are pathways relevant to inflammatory, vascular, and reproductive disease research. However, **these observations are general pharmacological knowledge and are not derived from the Evidence Pack**, and must not substitute for a formal TxGNN prediction before any repurposing decision is made.

---

## Safety Considerations

Safety labelling data (TFDA package insert warnings and contraindications) was queried but returned no parseable content in the current run. Drug–drug interaction data was also not found.

> Please refer to the official package insert and TFDA SmPC for safety information before any clinical use or further evaluation.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline produced no predicted indications for Misoprostol, and two blocking/high-severity data gaps remain unresolved — specifically the absence of MOA data and safety labelling — making it impossible to complete even a preliminary repurposing assessment.

**To proceed, the following is needed:**

- **\[DG001 — Blocking\]** Retrieve TFDA package insert: download the PDF from the TFDA website and extract warnings, contraindications, and approved indication text. Without this, safety pre-screening (S1) cannot begin.
- **\[DG002 — High\]** Retrieve MOA from DrugBank API (DB00929): populate mechanism of action, drug targets, and pharmacodynamic pathways to enable TxGNN knowledge graph edge completion.
- **Re-run TxGNN prediction** after the two data gaps above are resolved and drug–graph edges are updated.
- **Investigate KG coverage**: confirm that Misoprostol's drug node is correctly linked to gene targets (PTGER1–4) and relevant disease nodes in the TxGNN knowledge graph; add missing edges if needed.
- If the re-run still returns zero predictions, escalate to manual literature review (PubMed search on Misoprostol + repurposing) and consider whether this drug is a suitable candidate for the current pipeline.
## Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning.
Klinisk validering krävs före klinisk tillämpning.

---

